Multiple Myeloma News and Research

Latest Multiple Myeloma News and Research

VELCADE based regimens are cost-effective for payers and patients, finds study

VELCADE based regimens are cost-effective for payers and patients, finds study

Updated safety data from Phase 2b 003-A1 study of carfilzomib announced

Updated safety data from Phase 2b 003-A1 study of carfilzomib announced

ImmunoGen reports encouraging clinical data of IMGN901

ImmunoGen reports encouraging clinical data of IMGN901

Bortezomib can improve control of GVHD and immune system recovery

Bortezomib can improve control of GVHD and immune system recovery

Dana-Farber Cancer Institute receives 2009 MMRC Center of the Year Award

Dana-Farber Cancer Institute receives 2009 MMRC Center of the Year Award

IMF to stage presentation on multiple myeloma at ASH annual meeting

IMF to stage presentation on multiple myeloma at ASH annual meeting

Cancer patient “Statement of Principles” brought to the 2009 ASH meeting

Cancer patient “Statement of Principles” brought to the 2009 ASH meeting

Financial aspects of cancer treatment reduces compliance

Financial aspects of cancer treatment reduces compliance

Medical research experts explore new strategies to speed up treatments for medical disorders

Medical research experts explore new strategies to speed up treatments for medical disorders

ImmunoCellular Therapeutics options immunotherapy targeting CSCs using abnormal Notch and Numb pathways

ImmunoCellular Therapeutics options immunotherapy targeting CSCs using abnormal Notch and Numb pathways

More than 80 abstracts highlighting Bristol-Myers Squibb's oncology compound to be presented

More than 80 abstracts highlighting Bristol-Myers Squibb's oncology compound to be presented

FDA grants Fast Track designation for Keryx Biopharmaceuticals' KRX-0401

FDA grants Fast Track designation for Keryx Biopharmaceuticals' KRX-0401

FDA grants Fast Track designation for AEterna Zentaris' perifosine

FDA grants Fast Track designation for AEterna Zentaris' perifosine

New data demonstrating the strength of Novartis' hematology portfolio to be presented

New data demonstrating the strength of Novartis' hematology portfolio to be presented

Data from brentuximab vedotin and dacetuzumab programs to be presented by Seattle Genetics

Data from brentuximab vedotin and dacetuzumab programs to be presented by Seattle Genetics

Acceleron Pharma announces study results of its ACE-011 and ACE-536 blood forming agents

Acceleron Pharma announces study results of its ACE-011 and ACE-536 blood forming agents

Calistoga Pharmaceuticals to present data on its CAL-101 inhibitor at the 51st ASH meeting

Calistoga Pharmaceuticals to present data on its CAL-101 inhibitor at the 51st ASH meeting

Smoothie Factory supports Chronic Disease Fund’s mission with holiday fundraising program

Smoothie Factory supports Chronic Disease Fund’s mission with holiday fundraising program

Clinical data on ImmunoGen's TAP compounds to be presented at the 51st ASH meeting

Clinical data on ImmunoGen's TAP compounds to be presented at the 51st ASH meeting

51st ASH meeting to feature 16 abstracts of MMRC

51st ASH meeting to feature 16 abstracts of MMRC